Abnormal Akt signalling in bladder epithelial cell explants from patients with interstitial cystitis/bladder pain syndrome can be induced by antiproliferative factor treatment of normal bladder cells

被引:7
作者
Keay, Susan K. [1 ,2 ]
Zhang, Chen-Ou [3 ]
机构
[1] Univ Maryland, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA
[2] US Dept Vet Affairs, Med Ctr, Med Serv, Baltimore, MD USA
[3] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
关键词
bladder epithelial cells; Akt; Wnt/frizzled; antiproliferative factor; interstitial cystitis/bladder pain syndrome; EPIDERMAL-GROWTH-FACTOR; GENE-EXPRESSION; URINE MARKERS; PROTEIN; PATHWAY; DIFFERENTIATION; CANCER; UROTHELIUM; RECEPTOR; PROLIFERATION;
D O I
10.1111/bju.13457
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To determine whether protein kinase B (Akt) signalling and secretion of specific downstream effector proteins are abnormal in specific cell fractions of bladder epithelial cells from patients with interstitial cystitis/bladder pain syndrome (IC/BPS), as explanted bladder epithelial cells from patients with IC/BPS produce a frizzled 8-related glycopeptide antiproliferative factor (APF) that inhibits normal bladder epithelial cell proliferation and expression of several proteins known to be regulated by Akt signalling. A related secondary objective was to determine whether treatment of normal bladder epithelial cells with active synthetic asialo-antiproliferative factor (as-APF) induces similar changes in Akt signalling and specific downstream effector proteins/mRNAs. Patients and Methods Cell proteins were extracted into four subcellular fractions from primary bladder epithelial explants of six patients who fulfilled modified National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) criteria for IC/BPS and six age-and gender-matched controls. Total and/or phosphorylated cellular Akt, glycogen synthase kinase 3 beta (GSK3 beta), and beta-catenin; total cellular JunB; and secreted matrix metalloproteinase 2 (MMP2) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) levels were determined by Western blot. MMP2, JunB, p53, uroplakin 3 (UPK3), and beta-actin mRNAs were quantified by quantitative reverse transcriptase-polymerase chain reaction. Akt activity was determined by nonradioactive assay. Results IC/BPS cells had lower Akt activity, along with lower Akt ser473- and GSK3 beta ser9-phosphorylation and higher beta-catenin ser33,37/thr41-phosphorylation in specific fractions as compared with matched control cells. IC/BPS explants also had evidence of additional downstream abnormalities compared with control cells, including lower nuclear JunB; lower secreted MMP2 and HB-EGF; plus lower MMP2, JunB, and UPK3 mRNAs but higher p53 mRNA relative to beta-actin. Each of these IC/BPS cell abnormalities was also induced in normal cells by as-APF. Conclusion These findings indicate that IC/BPS cells have abnormal Akt activity with downstream protein expression abnormalities including decreased MMP2 and HB-EGF secretion. They also support the hypothesis that APF plays a role in the pathogenesis of IC/BPS via its effects on cell Akt signalling and HB-EGF production.
引用
收藏
页码:161 / 172
页数:12
相关论文
共 50 条
  • [1] Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients
    Walker, Stephen J.
    Colaco, Marc
    Koslov, David S.
    Keys, Tristan
    Evans, Robert J.
    Badlani, Gopal H.
    Andersson, Karl-Erik
    GENOMICS DATA, 2014, 2 : 366 - 368
  • [2] Normalization of Proliferation and Tight Junction Formation in Bladder Epithelial Cells from Patients with Interstitial Cystitis/Painful Bladder Syndrome by d-Proline and d-Pipecolic Acid Derivatives of Antiproliferative Factor
    Keay, Susan
    Kaczmarek, Piotr
    Zhang, Chen-Ou
    Koch, Kristopher
    Szekely, Zoltan
    Barchi, Joseph J., Jr.
    Michejda, Christopher
    CHEMICAL BIOLOGY & DRUG DESIGN, 2011, 77 (06) : 421 - 430
  • [3] Assessment of bladder pressure and discomfort symptoms: How do overactive bladder differ from interstitial cystitis/bladder pain syndrome patients?
    Angelíca Gousse
    Joel Vetter
    H. Henry Lai
    BMC Urology, 23
  • [4] Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome
    Abid, Md Shadman Ridwan
    Qiu, Haowen
    Tripp, Bridget A.
    Leite, Aline de Lima
    Roth, Heidi E.
    Adamec, Jiri
    Powers, Robert
    Checco, James W.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] Current standard of care in treatment of bladder pain syndrome/interstitial cystitis
    Lopez, Sabela Rodriguez
    Mangir, Naside
    THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
  • [6] Disability in women suffering from interstitial cystitis/bladder pain syndrome
    Katz, Laura
    Tripp, Dean A.
    Nickel, J. Curtis
    Mayer, Robert
    Reimann, Maria
    van Ophoven, Arndt
    BJU INTERNATIONAL, 2013, 111 (01) : 114 - 121
  • [7] Epigenetic Reprogramming: A Possible Etiological Factor in Bladder Pain Syndrome/Interstitial Cystitis?
    Elgavish, Ada
    JOURNAL OF UROLOGY, 2009, 181 (03) : 980 - 984
  • [8] Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome
    Wen, Chao
    Xie, Liping
    Hu, Chenxia
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (03) : 624 - 635
  • [9] Bladder Pain Syndrome Associated with Interstitial Cystitis: Recent Research and Treatment Options
    Wan-Ru Yu
    Yuan-Hong Jiang
    Jia-Fong Jhang
    Hann-Chorng Kuo
    Current Bladder Dysfunction Reports, 2023, 18 : 389 - 400
  • [10] Bladder Pain Syndrome Associated with Interstitial Cystitis: Recent Research and Treatment Options
    Yu, Wan-Ru
    Jiang, Yuan-Hong
    Jhang, Jia-Fong
    Kuo, Hann-Chorng
    CURRENT BLADDER DYSFUNCTION REPORTS, 2023, 18 (04) : 389 - 400